Biotech Startups

Calla Lily Clinical Care is a women's health company developing intravaginal drug delivery products based on its proprietary Callavid platform device, targeting IVF, prevention of preterm birth and miscarriage, delivery of live biotherapeutics to restore the vaginal microbiome, and biomarker sample collection for diagnostics such as endometriosis. Its FDA-cleared device technology serves the women's health and medical device market.

1 investor

Developing intra-articular ion channel modulator therapeutics for osteoarthritis of the knee.

1 investor

Calycia Bioscience is a biotechnology company developing engineered macrophage cell therapies delivered locally into the brain to target aggressive solid tumors of the central nervous system. Its pipeline focuses on glioblastoma and melanoma brain metastasis within CNS oncology.

1 investor

Calyxha is a biotech company developing novel small molecule anti-inflammatory drugs for multiple inflammatory diseases. Its lead product, CAL-4, is in preclinical development as an alternative to corticosteroids for asthma.

1 investor

Cambiotics develops a precision-formulated probiotic whose bacterial strains interact with PFAS ("forever chemicals") in the gut to support their removal from the body through the digestive system. Based on University of Cambridge research, it targets consumers exposed to PFAS, including first responders such as firefighters and military personnel, with a US product launch planned for 2026.

1 investor

Cambrex provides pharmaceutical supply chain management and manufacturing services focused on supply chain resilience through dual sourcing and contingency planning to ensure reliable product delivery during disruptions.

1 investor

Cambridge Nucleomics develops a single-molecule RNA counting "nanoarray" assay based on solid-state nanopore and DNA nanotechnology for diagnostic testing. The company applies its technology to RNA biology and microbiology-based diagnostics.

1 investor

1 investor

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.

1 investor

Cambridge Vision Technology develops diagnostic hardware and software for detecting Alzheimer's disease and other neurodegenerative conditions through retinal imaging and biomarker analysis. The company serves healthcare providers seeking early, non-invasive screening tools for preclinical Alzheimer's disease risk.

1 investor

Ajinomoto Cambrooke develops, manufactures, and commercializes therapeutic nutrition products for patients with chronic and metabolic medical conditions. It serves the medical community with formula-based nutritional therapies aimed at improving clinical outcomes and patient quality of life.

1 investor

Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.

1 investor

Based in Research Triangle Park, NC

1 investor

novoLUX develops science-based skincare using LNP3, a patented triple-layer lipid nanoparticle technology that delivers peptides, exosomes, and PDRN with sustained release. The products target specific skin concerns such as acne-prone skin, post-procedure repair, dryness, hyperpigmentation, fine lines, and radiance.

1 investor

Canbiocin provides product development services for companies seeking to formulate and manufacture functional food or beverage products containing prebiotics, probiotics, and postbiotics. The company guides clients through the complete innovation process from concept through production and market launch.

1 investor

Cancer Focus Fund is a venture capital firm that invests in cancer-focused companies and life science ventures. The fund supports biotech and healthcare companies working on cancer treatment and research.

1 investor

Cancer Free provides personalized cancer drug testing services using blood samples to create in vitro tumor models (avatar medicine) that allow physicians to test multiple drug combinations before patient treatment. The platform serves oncologists and cancer patients across multiple drug categories including chemotherapy, hormone therapy, and targeted therapy.

1 investor

Cancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.

1 investor

Emergent is a public health company that develops and manufactures medical countermeasures and protective solutions for endemic public health threats, national security preparedness, and supports biopharma innovators and organizations with manufacturing.

1 investor

Cansativa is a wholesaler of medical cannabis, supplying pharmacies, industry, and public-sector partners with cannabis products across its brands (N!CE, AMICI, Peace Naturals, Lit). Based in Germany, it focuses on distribution of medical cannabis and international market expansion within Europe.

1 investor

CanSino Biologics develops and manufactures vaccines, including tetanus, whooping cough, pneumococcal, meningococcal, and COVID-19 vaccines for prevention of infectious diseases. The company serves healthcare systems and immunization programs, primarily in China and Asia.

1 investor

Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease. The company operates in the therapeutics and biotech space.

1 investor

Cantargia is a company listed on Nasdaq Stockholm (Small Cap). The page presents shareholder and stock information, including its largest owners.

1 investor

Cantoni Therapeutics develops small molecule inhibitors targeting nicotinamide N-methyltransferase (NNMT) for the treatment of metabolic and oncology diseases. The company is a discovery and preclinical stage biotech enterprise based in the Netherlands.

1 investor